Autosomal dominant polycystic kidney disease (ADPKD) is a multisystem disorder characterized by renal, hepatic and pancreatic cyst formation and cardiovascular complications. The condition is caused by mutations in the PKD1 or PKD2 gene. In mice with reduced expression of Pkd1, dissecting aneurysms with prominent media thickening have been seen. To study the effect of selective disruption of Pkd1 in vascular smooth muscle cells (SMCs), we have generated mice in which a floxed part of the Pkd1 gene was deleted by Cre under the control of the SM22 promotor (SM22-Pkd1 del/del mice). Cre activity was confirmed by X-gal staining using lacZ expressing Cre reporter mice (R26R), and quantitative PCR indicated that in the aorta Pkd1 gene expression was strongly reduced, whereas Pkd2 levels remained unaltered. Histopathological analysis revealed cyst formation in pancreas, liver and kidneys as the result of extravascular Cre activity in pancreatic ducts, bile ducts and in the glomerular Bowman's capsule. Remarkably, we did not find any spontaneous gross structural blood vessel abnormalities in mice with somatic Pkd1 gene disruption in SMCs or simultaneous disruption of Pkd1 in SMCs and endothelial cells (ECs). Extensive isometric myographic analysis of the aorta did not reveal differences in response to KCl, acetylcholine, phenylephrin or serotonin, except for a significant increase in contractility induced by phenylephrin on arteries from 40 weeks old Pkd1 del/ þ germ-line mice. However, SM22-Pkd1 del/del mice showed significantly reduced decrease in heart rate on angiotensin II-induced hypertension. The present findings further demonstrate in vivo, that adaptation to hypertension is altered in SM22-Pkd1 del/del mice.
Autosomal dominant polycystic disease (ADPKD) is one of the most common inherited diseases, affecting 1:1000 individuals worldwide. The disease is characterized by progressive kidney enlargement and destruction of the normal renal tissue by many fluid-filled cysts, and progresses to endstage renal failure (ESRF) in most patients. However, it is a slowly progressive disease with ESRF usually around the age of 60. 1 Approximately 85% of cases are because of PKD1 mutations and in 15% the disease is caused by a mutation in PKD2.
2 Both PKD1 and PKD2 are expressed in a variety of cell types and tissues including renal epithelium, hepatic bile ducts, pancreatic ducts, vascular smooth muscle cells (SMCs) and endothelial cells (ECs). [3] [4] [5] ADPKD is also associated with cysts in the liver and pancreas as well as cardiovascular complications such as hypertension and aneurysms. 6 High blood pressure is very common in ADPKD, and occurs in the majority of patients before any substantial reduction in renal function is observed. Furthermore, hypertension occurs at a much earlier age in patients with ADPKD than in the general population and is also associated with a rapid progression toward renal failure and increased cardiovascular complications (for review see ref. 7) . The prevalence of cerebral aneurysms in ADPKD patients is approximately 10-fold higher than in the general population and about 27% among ADPKD patients with a family history for aneurysms. 8, 9 Aneurysmal involvement of extracranial arteries, such as the coronary arteries, abdominal aorta, renal artery and splenic artery has also been reported in patients with ADPKD (for review see ref. 7) . Several mouse models have been established to study ADPKD using targeted disruption of the Pkd1 or Pkd2 gene. Homozygous Pkd1 and Pkd2 knock-out mice die in utero, around embryonic day 15, because of severe cystic disease, vascular defects and/or abnormalities of the placental labyrinth, whereas heterozygous Pkd1 knock-out mice showed minimal renal cyst formation in adulthood. 4, [10] [11] [12] [13] [14] [15] Furthermore, we described a Pkd1 mouse (hypomorphic) model, with low expression of Pkd1 showing progressive polycystic kidney disease and aortic dissecting aneurysms, indicating that Pkd1 is implicated in the structural integrity and function of the vasculature. 16, 17 In the hypomorphic Pkd1 nl,nl mice a very prominent media thickening was seen in most of the animals analyzed. As SMCs is the most abundant cell type in the media, we set out to study the effect of Pkd1 gene disruption in vascular SMCs on blood vessel function. To this aim, we generated mutant mouse lines with a targeted disruption of the Pkd1 gene in SMCs, by crossing mice containing floxed Pkd1 alleles with SM22Cre. We previously showed that Pkd1 gene disruption in vascular SMCs results in a reduced myogenic tone. 18 Functional roles for the polycystins in mechanosensation have been proposed in ECs as well as SMCs. In ECs, the proteins are involved in fluid shear stress sensing, thereby regulating calcium signaling and nitric oxide release. This affects the vasodilatation in response to increased blood flow. 19 In vascular SMCs, the polycystins regulate the activity of the stretch-activated cation channels. In mice with reduced Pkd1 expression in SMCs, stretch-activated channel (SAC) activity was decreased and the threshold pressure for myogenic contraction was significantly shifted to higher pressure values. 18 The ratio of polycystin-1/polycystin-2 regulates SACs activity, as polycystin-2 inhibits channel opening, whereas polycystin-1 reverses this inhibition. 18 It is likely that alterations in intracellular Ca 2 þ homeostasis contribute to the vascular phenotype in PKD. 20, 21 In this study, we show that disruption of the Pkd1 gene in these cells did not induce gross structural abnormalities in blood vessels, even not when Pkd1 was disrupted in ECs, as well. However, an increase in blood pressure in SM22-Pkd1 del/del mice, induced by angiontensin II treatment, resulted in reduced heart rate adaptation.
MATERIALS AND METHODS Mice
The generation of Pkd1 del2-11 and Pkd1 lox2-11 alleles has been described previously. 17, 22 The Pkd1 lox2-11 (Pkd1 lox ) allele contains two loxP sites inserted into intron 1 and 11. In the presence of the DNA recombinase Cre, the loxP flanked sequence was deleted to form the Pkd1 23 All experiments using mice were approved according to the Dutch and French law and conform with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH publication no. 85-23, revised 1996). Approval was granted by a local ethics review board.
PCR for Pkd1 Gene Disruption in ECs and Vascular SMCs
Genotypes were assessed by PCR analysis of tail genomic DNA using a reverse primer in intron 11 combined with a forward primer in intron 1 (del allele) or a forward primer in intron 11 (floxed and wild-type alleles) as described previously for genotyping of strains. 22 Real-Time Quantitative PCR Quantitative PCR was performed on mRNA isolated from aortas of 30-week-old SM22-Pkd1 del/del , SM22-Pkd1
and control mice. For quantitative PCR (qPCR) analysis, primer sequences are as follow: Pkd1: forward: GCC ATC CAG CAC TTC CTA GT, reverse: GAG AAG CCG ATC CAC ACA TC; Pkd2: forward: AGGTGTTAGGACGGCTGCT, reverse: CCCTGTGGATCTCACTGTCC. qPCR data were normalized to the mouse Top1 reference gene expression amplified using the following primers: Top1: forward: GCCTCCATCACACTACAGCA and reverse: TTCGCTGGT ACATTCTCATCA. qPCR data were analyzed using the LightCycler 480 software release 1.5.0 and Excel program, as described previously.
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Immunohistochemistry Histological analysis was performed on aortas (from aortic root to the bifurcation of the iliac arteries), pancreas, liver and kidneys. The organs were dissected and fixed in 4% paraformaldehyde in 0.1 M sodium phosphate buffer for 24 h. Fixed tissues were dehydrated in graded ethanol and xylene and embedded in paraffin. Sequential sections of 4 mm were mounted onto Superfrost-plus glass slides. After deparaffinization, sections were stained using standard procedures. 24 Sections were incubated in 0.1 mg/ml pronase before incubation with CD31 (PECAM) and Lyve-1 antibodies. The monoclonal 1A4 antibody (a-SM-actin) and secondary antibody rabbit-anti-mouse peroxidase (RAM-PO) were first incubated to form 1A4-RAM-PO complex before adding it on sections following a previously described procedure. 25 The 
X-Gal Staining
Tissues of 3-day-old SM22Cre; R26R and Tie2Cre;R26R mice and controls were stained whole mount for X-gal (see Supplementary Methods). After washing tissues were post-fixed overnight in phosphate-buffered 4% formaldehyde and further processed for embedding in paraffin. Sections of 4 mm were cut and counter stained with 0.1% nuclear fast red and 5% Al 2 (SO 4 ) 3 for 5-10 s.
Tail Cuff Measurements and Osmotic Pumps Implantation Systolic blood pressure and heart rate were measured by the tail cuff method (BP2000, Visitech), at 371C to dilate the tail artery, five times weekly and averaged for each week. SM22-Pkd1 del/del and control wild-type mice (50% Pkd1 lox/lox and 50% SM22Cre), 30 weeks old, were habituated to the measurement for 3 weeks before implantation of the pumps and then monitored during about 4 weeks. The osmotic pumps (Alzet model, 2004) were implanted subcutaneously on the back of the animals and continuously delivered a dose of 0.61 mg per kg per day of angiotensin II (AngII; Sigma) in phosphate buffer saline. Systolic blood pressure and heart rate were recorded simultaneously. Significance of the two groups was tested with a permutation test (non-parametric test) at a threshold of 5%; StatXact software).
To study the effects of elevated blood pressure on vessel structure, the thoracic aortas of control (Pkd1 lox/lox and SM22Cre) and SM22-Pkd1 del/del mice were observed. Fixation was carried out by perfusion with Bouin's fixative (formalin/ picric acid) in the animal during 10 min and after removal from the animal in 10% neutral-buffered formalin. Tissues were paraffin-embedded, sectioned, and stained with combined orcein (dark elastin staining) and picro-indigo-carmin (blue collagen staining).
Wire Myography A 2 mm long segments of thoracic aorta were mounted on a wire myograph (DMT, Aarhus, Denmark; isometric myography). 27 Two steel wires (40 mm in diameter) were inserted into the artery lumen and fixed to a force transducer and a micrometer, respectively. A normalization procedure was used to evaluate the internal circumference that the aorta would have under a transmural pressure of 100 mm Hg (IC 100). To obtain a maximal and uniform response, all experiments were carried out at 90% of this internal circumference (IC 90). Arteries were bathed in a physiological solution (PSS), which composed of (in mM) NaCl 119; KCl 4.7; CaCl 2 2.5; MgSO 4 1.17; NaHCO 3 25; KH 2 PO 4 1.18; EDTA 0.027; glucose 5.5, oxygenated with a mixture of CO 2 (5%) and O 2 (95%), or the same PSS solution containing 80 mM KCl (NaCl substituted by KCl), named PSS 80K. Before each experiment, the contractility of the muscle was tested using the PSS 80K solution and then phenylephrin (1 mM) in standard PSS. The integrity of the endothelium was assessed by verifying that at least a 70% relaxation effect was obtained with acetylcholine (5 mM) after a precontraction by phenylephrin (1 mM). For each mouse, between two to four responding aorta rings were measured and averaged, error bars indicates the standard error to the mean, n indicates the number of mice. Significance was tested with a permutation test (R; R Development Core Team: http://www.r-project.org/) at a threshold of 5% (*), 1% (**) and 1% (***). Cumulative dose response curves of phenylephrin, serotonin (5HT) and U46619 (thromboxan A2 agonist) were realized with extensive washout in between each curve. The cumulative dose response curve of acetylcholine was made after a precontraction with phenylephrin (1 mM). Experiments were performed on heterozygous SM22-Pkd1 del/ þ mice and controls (SM22Cre and Pkd1 lox/ þ ), homozygous SM22-Pkd1 del/del mice and their controls (SM22Cre and Pkd1 lox/lox ) at 11 weeks, as well as heterozygous SM22-Pkd1 del/ þ mice and their controls and the germ-line Pkd1 del/ þ and wild types, on mice aged 40 weeks.
RESULTS

Inactivation of Pkd1 in Smooth Muscle and ECs Does Not Result in Gross Structural Blood Vessel Abnormalities
To inactivate Pkd1 in SMCs, we crossed Pkd1 del/lox and Pkd1 del/lox mice with SM22Cre mice to yield SM22-Pkd1 del/del . We carefully analyzed aortas of six SM22-Pkd1 del/del mice (age 6 months) with Pkd1 gene disruption in SMCs but did not see any abnormalities. As the matrix metalloproteinase (MMP)-2 and -9, are key activators in blood vessel remodeling we performed zymography to analyze MMP-2 and MMP-9 activity. No differences were observed between the different genotypes (not shown). Subsequently, we inactivated Pkd1 in both SMCs and ECs by crossing
SM22-Pkd1
del/del with Tie2-Pkd1 del/del mice to yield SM22; Tie2-Pkd1 del/del mice. We carefully analyzed aortas of four SM22;Tie2-Pkd1 del/del mice (age 6 months). Also these aortas were morphologically normal (Figure 1a-c Inactivation of Pkd1 in SM22Cre Expressing Cells Induces Cysts in Pancreas, Liver and Kidneys All neonatal SM22-Pkd1 del/del mice (age 3 and 4 days, n ¼ 7) showed a few large and small pancreatic cysts (Figure 1f ) as well as dilated glomeruli in kidneys. The liver showed no cysts at this age. Most mice survived and were killed at the age of 6 months, (n ¼ 10) large cysts were found in pancreas, liver and kidneys (Figure 1g -i).
Cysts in pancreas and liver were surrounded by spindlelike cells, which were positive for a-smooth muscle actin (a-SMA, not shown) indicating infiltration of myofibroblasts ( Figure 1 , insets in g and h). The cysts were localized in groups, and few cysts were hyperplastic. In the pancreas, the cystic phenotype was more progressive compared with kidneys and liver, with larger numbers and sizes of cysts. Cysts in the pancreas and liver seem to originate from the pancreatic ducts and bile ducts, respectively, whereas no loss of pancreatic acini or hepatocytes in liver were detected.
In the kidneys, a few dilated glomeruli, one to six dilatations per section, were found in neonates at day 3. In 6-month-old mice, large cysts were found and many of these cysts contained the glomerular tuft, which stained for the endothelial marker CD31, indicating the presence of glomerulus-derived cysts (Figure 1i ). Not all glomeruli were dilated and kidneys showed many normal glomeruli as well. 23 X-gal staining of SM22Cre;R26R (age 3 days, n ¼ 2) aortas, revealed that efficient recombination of the reporter construct had occurred in SMCs in the media and the adventitia, resulting in expression of the LacZ gene (Figure 1d ). In Tie2Cre;R26R (age 3 days, n ¼ 1), LacZ expression was found in most ECs in the intima (Figure 1e ).
Pkd1 gene disruption by Cre was confirmed by PCR analysis of the DNA derived from the tails of mice carrying the Pkd1 lox/ þ alleles as well as SM22Cre or Tie2Cre (Figure 2a ). Even more, quantitative PCR revealed a strong reduction in Pkd1 mRNA levels in aorta's of SM22-Pkd1 del/del mice compared with SM22-Pkd1 del/ þ and controls, whereas Pkd2 mRNA levels remained unaltered (Figure 2b ).
Cre Activity in Pancreas, Liver and Kidneys of SM22Cre and Tie2Cre Mice
To explain the phenotype of the SM22-Pkd1 del/del mice, we analyzed Cre activity in the kidneys, liver and pancreas in SM22Cre;R26R mice (age 3 days). X-gal staining was found in all three organs and it matched with the origin of cyst formation found in these organs in SM22-Pkd1 del/del mice. In the pancreas, many serous acini and the ducts were positive for lacZ expression (Figure 1j ). In the liver, expression was found in most bile ducts and in mesenchymal cells around the ducts (Figure 1k ). In addition, blood cell precursors, eg, myeloblasts, myelocytes, granulocytes and megakaryocytes were also positive for lacZ. Hepatocytes did not show lacZ expression. The kidneys showed lacZ expression in the parietal layer of Bowman's capsule of mature glomeruli ( Figure  1l ). The control R26R mice, without the Cre transgene, did not show X-gal staining, except for a subset of proximal tubules. This was also found in the renal cortical tubules of SM22Cre;R26R and Tie2Cre;R26R, indicating non-specific signal (Figure 1l) . SMCs of blood vessels in all organs were positive for X-gal.
Deletion of Pkd1 under the control of Tie2 promotor did not result in a phenotype. Tie2Cre;R26R reporter mice, neonatal age 3 days, showed lacZ expression in ECs in large vessels (Figure 1e ), in capillaries, and in blood cell precursors (not shown), which is in line with previous reports. 28 
Selective Inactivation of Pkd1 in SMCs does not Affect Contractility
To analyze whether Pkd1 gene deletion has more subtle effects on vascular function, several series of isometric myographic analyses were performed on aortas. First, heterozygous SM22-Pkd1 del/ þ mice and controls as well as homozygous SM22-Pkd1 del/del mice and their controls were analyzed at 11 weeks . Three bands can be seen for both Tie2-Pkd1 lox/wt and SM22-Pkd1 lox/wt mice; the wild-type (wt) Pkd1 allele (Pkd1 wt ), the floxed Pkd1 allele (Pkd1 lox ) and the partially deleted Pkd1 (Pkd1 del ) indicating that floxed Pkd1 allele is deleted on Cre expression in both mouse models. The intensity of the 366-bp deletion-specific PCR product is relatively weak compared with the floxed or wt alleles, as Cre-mediated recombination occurred only in smooth muscle cells or endothelial cell, respectively. In control mice, without Cre, the deletionspecific product was absent. *Po0.05.
Vascular SMCs Pkd1 inactivation S Hassane et al of age (Figures 3a-c) . At this age the IC 90 (internal diameter at 90 mm Hg pressure) is small, around 415 mm, and vasoconstriction induced by phenylephrin is low (0.2 mN/mm at 10 À5 M; Figure 3c ). No differences were observed between the different genotypes (Figure 3c ). We also found no differences between IC 90 at vasoconstriction obtained with passive depolarization of the vessels with 80 mM KCl (PSS 80 K), between activation curves obtained with serotonin or the vasoconstrictor U46619, and when looking at dilatation obtained with acetylcholine (Figures 3a and b) .
Next series of measurements were performed on the heterozygous SM22-Pkd1 del/ þ mice and their controls, as well as the germ line Pkd1 del/ þ (which carry a deletion allele in all cells) and wild-type controls, both performed on older mice, aged 40 weeks (Figures 3d-i) . The homozygous mutants SM22-Pkd1 del/del were not available because of the cystic phenotype (see above). No differences were found between the IC 90, with 1029 ± 16 mm and 1053 ± 9 mm for SM22-Pkd1 del/ þ (n ¼ 10) and their controls (n ¼ 16), respectively, (P ¼ 0.49), and with 967 ± 10 mm and 979 ± 10 mm for Pkd1 del/ þ (n ¼ 17) and their control wild types (n ¼ 12), respectively, (P ¼ 0.79). The vasodilatation induced by acetylcholine was not significantly different in both series of experiments (Figures 3d and g ). The vasoconstriction induced by and their controls (Figure 3f ). Interestingly, they were significantly higher in the germ-line Pkd1 del/ þ mice compared with wild type (P ¼ 0.007 at 3 mM), as previously reported by Morel et al (2009) for 30-week-old mice (Figure 3i ). 20 Increased Blood Pressure Induces Mild Media Thickening and Impaired Adjustment of Heart Rate in SM22-Pkd1 del/del Mice As the hypomorphic Pkd1 nl/nl mice show a strong renal cystic phenotype, it is anticipated that those mice have an elevated blood pressure, which could contribute to the vascular pathology. As baseline arterial pressure was not altered in SM22-Pkd1 del/del mice compared with controls. 18 We induced high blood pressure by the infusion of AngII (Figure 4) . Histological analysis induced mild media thickening but did not reveal gross structural differences between Angiotensin II treated SM22-Pkd1 del/del mice and controls (not shown). Interestingly, AngII induced decrease in the heart rate was significantly less pronounced in SM22-Pkd1 del/del (P ¼ 0.041, at 3 weeks), although the systolic pressure response was not different (Figures 4a and b) .
DISCUSSION
Previously, we analyzed a Pkd1 hypomorphic mouse model, Pkd1 nl/nl , with reduced levels of Pkd1 transcripts in the aortas and kidneys. 16 These mice showed dissecting aneurysm formation with very prominent abnormalities in the media and mild intima involvement. In addition, they have severe polycystic kidney disease.
In this study, we generated mouse models to analyze the consequences of the specific deletion of Pkd1 in SMCs, which are the major component of the media. These mice, however, did not show any structural alterations of the aortic vessel wall in mice analyzed up to 6 months. Moreover, disruption of Pkd1 simultaneously in SMCs and ECs did not result in structural blood vessel alterations, even though the recombination levels were high in blood vessels as shown by the Cre reporter and by strongly reduced Pkd1 mRNA levels. This is in agreement with the early expression of endogenous SM22 and Tie2 genes, around embryonic day 8. 29, 30 Our data indicate that Pkd1 gene disruption in SMCs alone and/or in ECs is not sufficient to induce gross structural abnormalities in the aorta, suggesting that additional triggers are needed to induce or to accelerate the phenotype. For the renal cystic phenotype, we previously showed that the renal injury is a trigger that strongly accelerates the polycystic kidney disease. 31 Extensive isometric myographic analysis did also reveal that no difference in response to KCl, acetylcholine, phenylephrin, U46619 or serotonin was observed in young mice (11 weeks) or in older mice (40 weeks), in heterozygous or in homozygous animals with a selective disruption of Pkd1 in SMCs. Only the 40-week-old heterozygous Pkd1 del/ þ mice, which carry a deletion allele in all cells, show a significant increase in vascular contractility in response to phenylephrin. This increase has been previously reported in the same mutants aged 30 weeks, whereas at 12 and 20 weeks no differences were observed. 17 Our results suggest that heterozygous Pkd1 gene disruption in vascular SMCs is not sufficient to explain the increased phenylephrin response in Pkd1 del/ þ mice and that other cell types probably contribute to this vascular phenotype. In addition, the effect is building up over time.
Importantly, although we did not observe spontaneous structural alterations in the aorta's of SM22-Pkd1 del/del mice, these mice showed a decreased myogenic tone in resistance arteries. 18 Interestingly, the ratio of polycystin-1/polycystin-2, which is disturbed in the deletion mutants, is of crucial importance for the regulation of stretch-activated ion channels (SACs) in arterial myocytes. 18 Activation of SACs When we implanted the AngII-releasing pumps to induce hypertension, the heart rate significantly slowed down in all genotypes. This decrease in heart rate is the result of adaptation of the cardiac outflow to increased peripheral resistance and/or to the central nervous system effect of angiotensin. 32, 33 Interestingly, in the homozygous SM22-Pkd1 del/del mice, this decrease in heart rate is significantly less prominent compared to the control mice. Cardiac output (stroke volume Â heart rate) is known to drop upon an increase in blood pressure, as for instance induced by AngII infusion. 34 However, according to the classical Guyton model (Guyton et al, 1972) , without autoregulation (ie, myogenic tone), cardiac output in response to hypertension is predicted to remain high. 32, 34 This model fits nicely with our data as anticipated by a loss of myogenic tone in SM22-Pkd1 del/del mice. 18 Indeed, in these mice, the decrease in heart rate (ie, cardiac output) is significantly less prominent compared with the control mice. Another possible mechanism of the hypertension-induced bradycardia may include a central effect through AT1 receptors in the central nervous system. 33 Several other explanations could be given why without additional triggers the hypomorphic Pkd1 nl/nl mice, and also Pkd1 knock-out mice, show structural abnormalities of the blood vessels at neonatal or embryonic stages, respectively, while the SM22;Tie2-Pkd1 del/del mice do not. 4, 10, 11, 16 The genetic background may affect the process of blood vessel remodeling, as the complex mouse models used in this study consisted of a mixture of different genetic backgrounds. Furthermore, low Pkd1 expression in other cell types than SMCs and Ecs, in which Pkd1 is not disrupted in the SM22;Tie2-Pkd1 del/del mice (for instance immune cells), may contribute to the process of aneurysm formation in Pkd1 nl/nl mice, thereby accelerating the process. Therefore, it will be interesting to study the effects of increased blood pressure in SM22;Tie2-Pkd1 del/del mice on full C57BL/6 background in future experiments.
Although no spontaneous structural abnormalities of the vasculature were detected, we observed cyst formation in pancreas, liver and kidneys, when the Pkd1 gene was deleted under the control of SM22 promotor. Expression of LacZ matched with the sites of cyst formation and was found in pancreatic ducts and hepatic bile ducts, which are the origin of the cysts. In the kidneys, only glomerular cysts were found and recombination did occur in the parietal layer of Bowman's capsule of glomeruli. It is known that Pkd1 is also expressed in pancreatic ducts, hepatic bile ducts and Bowman's capsule, and thus coincides with the origin of the cysts as well. 5, 35, 36 These cysts can be found in ADPKD patients as well. Our data indicate that the SM22 promoter fragment that regulates the expression of Cre is not exclusively expressed in vascular SMCs. Expression of the promoter in specific mesenchymal cells during the development may explain the observed expression pattern. 37 Despite the presence of large cysts, the function of the pancreas was not severely affected, as no loss of acini was found and there was no starch present in the colon, indicating a sufficient level of digestion (not shown). In the liver, no loss of hepatocytes was noticed either. Furthermore, the mutant kidneys showed many normal glomeruli beside the dilated ones. These results may explain why the mutant mice were able to survive for several months even with the presence of large cysts, especially in the pancreas.
The renal glomerular cystic phenotype was relatively mild and did not affect the blood pressure. Glomerular cysts can also be found as part of ADPKD, predominantly in fetal kidneys and also in adult end-stage kidneys, in addition to tubular cysts. 38, 39 In addition, glomerular cysts can develop as distinct entity, glomerulocystic kidney disease or in the context of several other renal diseases. [40] [41] [42] Also in Pkd1-mutant mouse models glomerular cysts have been observed. These cysts were only observed in Pkd1 knock-out mice but not in hypomorphic mice that have low levels of Pkd1 gene expression, suggesting that total absence of Pkd1 is necessary to induce the formation of glomerular cysts. 10, 11, 15, 17, 43, 44 How these cysts arise is not entirely clear. As Pkd1 is deleted in Bowman's capsule, the suggested mechanism that urinary tract infections lead to increased pressure in Bowman's space seems not very likely in SM22-Pkd1 del/del mice. 45 Defects in cilia signaling, cellular signaling, cell-cell and cell-matrix interactions, which have been observed in ADPKD tubular cysts, probably have a more important role. In addition, as polycystin-1 is known to affect migration and proliferation, 46 ,47 the absence of Pkd1 might disturb the recruitment of podocytes from the glomerular parietal epithelial cells, which proliferate and migrate into the glomerular tuft and differentiate into podocytes. 48 In conclusion, targeted deletion of Pkd1 in SMCs does not induce major structural blood vessel abnormalities, spontaneously, in mice. Increased blood pressure, however, revealed a mildly reduced adaptation of the heart rate. It remains to be determined whether the decrease in myogenic tone observed in these mice is involved in this phenotype. 18 
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